Daniel P Dolan, Geriam Ruiz-Barreto, Miles McAllister, Fatemehsadat Pezeshkian, Hao Li, Yue Xie, Emanuele Mazzola, Scott J Swanson, Michael T Jaklitsch, Jon O Wee
{"title":"放化疗后延迟食管切除术与死亡率或复发率增加无关。","authors":"Daniel P Dolan, Geriam Ruiz-Barreto, Miles McAllister, Fatemehsadat Pezeshkian, Hao Li, Yue Xie, Emanuele Mazzola, Scott J Swanson, Michael T Jaklitsch, Jon O Wee","doi":"10.1002/jso.70084","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of delayed esophagectomy on the overall survival of esophageal cancer patients undergoing esophagectomy after CROSS.</p><p><strong>Methods: </strong>A retrospective analysis was done of a prospective database of esophagectomy patients who underwent CROSS therapy and esophagectomy from May 2016 to January 2020. Preoperative characteristics, postoperative adverse events, recurrence rates, and survival rates were compared between patients who underwent surgery within 60 days of CROSS completion versus > 60 days.</p><p><strong>Results: </strong>In total, 197 patients were included; 137 underwent surgery within 60 days (standard group, SG) versus 60 at > 60 days (delayed group, DG). Median time to surgery was 43 versus 76 days for the SG and DG groups. Median follow-up was 60 months. No differences were observed for gender, race, home state, Eastern Cooperative Oncology Group score, and tumor characteristics. DG patients were older; had higher Charlson Comorbidity Scores; and more history of myocardial infarction, stroke, and smoking, all p ≤ 0.05. DG had increased odds of major postoperative adverse events (odds ratio 2.26, 95% confidence interval 1.11-4.20). Overall survival and recurrence were similar.</p><p><strong>Conclusion: </strong>Following CROSS, a delay in esophagectomy beyond 60 days was not associated with worse recurrence or overall survival despite increased comorbidities and postoperative events.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Delayed Esophagectomy After Chemoradiation Is Not Associated With Increased Mortality or Recurrence.\",\"authors\":\"Daniel P Dolan, Geriam Ruiz-Barreto, Miles McAllister, Fatemehsadat Pezeshkian, Hao Li, Yue Xie, Emanuele Mazzola, Scott J Swanson, Michael T Jaklitsch, Jon O Wee\",\"doi\":\"10.1002/jso.70084\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the impact of delayed esophagectomy on the overall survival of esophageal cancer patients undergoing esophagectomy after CROSS.</p><p><strong>Methods: </strong>A retrospective analysis was done of a prospective database of esophagectomy patients who underwent CROSS therapy and esophagectomy from May 2016 to January 2020. Preoperative characteristics, postoperative adverse events, recurrence rates, and survival rates were compared between patients who underwent surgery within 60 days of CROSS completion versus > 60 days.</p><p><strong>Results: </strong>In total, 197 patients were included; 137 underwent surgery within 60 days (standard group, SG) versus 60 at > 60 days (delayed group, DG). Median time to surgery was 43 versus 76 days for the SG and DG groups. Median follow-up was 60 months. No differences were observed for gender, race, home state, Eastern Cooperative Oncology Group score, and tumor characteristics. DG patients were older; had higher Charlson Comorbidity Scores; and more history of myocardial infarction, stroke, and smoking, all p ≤ 0.05. DG had increased odds of major postoperative adverse events (odds ratio 2.26, 95% confidence interval 1.11-4.20). Overall survival and recurrence were similar.</p><p><strong>Conclusion: </strong>Following CROSS, a delay in esophagectomy beyond 60 days was not associated with worse recurrence or overall survival despite increased comorbidities and postoperative events.</p>\",\"PeriodicalId\":17111,\"journal\":{\"name\":\"Journal of Surgical Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Surgical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/jso.70084\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.70084","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Delayed Esophagectomy After Chemoradiation Is Not Associated With Increased Mortality or Recurrence.
Objective: To evaluate the impact of delayed esophagectomy on the overall survival of esophageal cancer patients undergoing esophagectomy after CROSS.
Methods: A retrospective analysis was done of a prospective database of esophagectomy patients who underwent CROSS therapy and esophagectomy from May 2016 to January 2020. Preoperative characteristics, postoperative adverse events, recurrence rates, and survival rates were compared between patients who underwent surgery within 60 days of CROSS completion versus > 60 days.
Results: In total, 197 patients were included; 137 underwent surgery within 60 days (standard group, SG) versus 60 at > 60 days (delayed group, DG). Median time to surgery was 43 versus 76 days for the SG and DG groups. Median follow-up was 60 months. No differences were observed for gender, race, home state, Eastern Cooperative Oncology Group score, and tumor characteristics. DG patients were older; had higher Charlson Comorbidity Scores; and more history of myocardial infarction, stroke, and smoking, all p ≤ 0.05. DG had increased odds of major postoperative adverse events (odds ratio 2.26, 95% confidence interval 1.11-4.20). Overall survival and recurrence were similar.
Conclusion: Following CROSS, a delay in esophagectomy beyond 60 days was not associated with worse recurrence or overall survival despite increased comorbidities and postoperative events.
期刊介绍:
The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.